%0 Journal Article %A JULIE LEMIEUX %A CAROLINE DIORIO %A MARC-ANDRÉ CÔTÉ %A LOUISE PROVENCHER %A FRÉDÉRIC BARABÉ %A SIMON JACOB %A CHRISTINE ST-PIERRE %A ÉRIC DEMERS %A ROSEMARIE TREMBLAY-LEMAY %A CORINNE NADEAU-LAROCHELLE %A ANNICK MICHAUD %A CHRISTIAN LAFLAMME %T Alcohol and HER2 Polymorphisms as Risk Factor for Cardiotoxicity in Breast Cancer Treated with Trastuzumab %D 2013 %J Anticancer Research %P 2569-2576 %V 33 %N 6 %X Background: Trastuzumab has no major side-effects except the potential for cardiac toxicity. The main objective of this study was to evaluate the association between trastuzumab-associated cardiac toxicity and two potential risk factors: alcohol intake and HER2 polymorphisms. Patients and Methods: In a retrospective cohort study of 237 women with non-metastatic HER2-positive breast cancer treated with trastuzumab, traditional risk factors were assessed by review of medical records, alcohol use by an administered questionnaire to women (n=132), and HER2 polymorphisms (Ile655Val and Ala1170Pro) using TaqMan assays (n=73). Results: Association was observed between alcohol intake (10 drinks and more per week) during the trastuzumab treatment and cardiac toxicity (p=0.04). For polymorphisms, compared to Ile/Ile carriers, HER2 Ile/Val was associated with a higher risk of cardiac toxicity (p=0.02). Conclusion: Heavy alcohol use during the course of trastuzumab treatment and the HER2 Ile/Val genotype may constitute risk factors for cardiac toxicity. %U https://ar.iiarjournals.org/content/anticanres/33/6/2569.full.pdf